The subject of this publication is the conclusion of agreements in accordance with Section 130 a (8) SGB V on finished medicinal products with various active substances or combinations of active substances within the framework of a so-called “open house model”.

The accession or the conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations are not carried out.

The earliest start date of the contract is 01.09.2023. Based on this, the contract period is a maximum of 24 months. The contract ends on 31.08.2025 regardless of the start of the contract.

If AOK Hessen should carry out an invitation to tender for exclusive contracts in the form of an open procedure during the contract period, the contracts concluded as part of this publication will be terminated in accordance with the contractual regulations.

Under stipulation of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to conclude or join a discount contract in accordance with Section 130a (8) SGB V for the active ingredients mentioned in Section B. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under I.1. The prerequisite for concluding a contract is that the interested pharmaceutical company must complete and sign the requested participation documents in full. A contract is concluded with each pharmaceutical company that meets the participation requirements. There is no exclusivity. This publication does not involve the award of a public contract in

The meaning of Directive 2014/24/EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form

the contract notice is used. The resulting conceptual requirements, such as the process name “open procedure”, are solely due to the use of this notice form and the publication platform. Another meaning, in particular submission to

Procurement regulations, unless they are mandatory for legal reasons, are not associated with this.

Under stipulation of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to conclude or join a discount contract in accordance with Section 130a (8) SGB V for the active ingredients mentioned in Section B. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under I.1. The prerequisite for concluding a contract is that the interested pharmaceutical company must complete and sign the requested participation documents in full. A contract is concluded with each pharmaceutical company that meets the participation requirements. There is no exclusivity. This publication does not involve the award of a public contract in

The meaning of Directive 2014/24/EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form

the contract notice is used. The resulting conceptual requirements, such as the process name “open procedure”, are solely due to the use of this notice form and the publication platform. Another meaning, in particular submission to

Procurement regulations, unless they are mandatory for legal reasons, are not associated with this.

Under stipulation of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to conclude or join a discount contract in accordance with Section 130a (8) SGB V for the active ingredients mentioned in Section B. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under I.1. The prerequisite for concluding a contract is that the interested pharmaceutical company must complete and sign the requested participation documents in full. A contract is concluded with each pharmaceutical company that meets the participation requirements. There is no exclusivity. This publication does not involve the award of a public contract in

The meaning of Directive 2014/24/EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form

the contract notice is used. The resulting conceptual requirements, such as the process name “open procedure”, are solely due to the use of this notice form and the publication platform. Another meaning, in particular submission to

Procurement regulations, unless they are mandatory for legal reasons, are not associated with this.

Under stipulation of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to conclude or join a discount contract in accordance with Section 130a (8) SGB V for the active ingredients mentioned in Section B. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under I.1. The prerequisite for concluding a contract is that the interested pharmaceutical company must complete and sign the requested participation documents in full. A contract is concluded with each pharmaceutical company that meets the participation requirements. There is no exclusivity. This publication does not involve the award of a public contract in

The meaning of Directive 2014/24/EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form

the contract notice is used. The resulting conceptual requirements, such as the process name “open procedure”, are solely due to the use of this notice form and the publication platform. Another meaning, in particular submission to

Procurement regulations, unless they are mandatory for legal reasons, are not associated with this.

Under stipulation of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to conclude or join a discount contract in accordance with Section 130a (8) SGB V for the active ingredients mentioned in Section B. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under I.1. The prerequisite for concluding a contract is that the interested pharmaceutical company must complete and sign the requested participation documents in full. A contract is concluded with each pharmaceutical company that meets the participation requirements. There is no exclusivity. This publication does not involve the award of a public contract in

The meaning of Directive 2014/24/EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form

the contract notice is used. The resulting conceptual requirements, such as the process name “open procedure”, are solely due to the use of this notice form and the publication platform. Another meaning, in particular submission to

Procurement regulations, unless they are mandatory for legal reasons, are not associated with this.

Under stipulation of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to conclude or join a discount contract in accordance with Section 130a (8) SGB V for the active ingredients mentioned in Section B. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under I.1. The prerequisite for concluding a contract is that the interested pharmaceutical company must complete and sign the requested participation documents in full. A contract is concluded with each pharmaceutical company that meets the participation requirements. There is no exclusivity. This publication does not involve the award of a public contract in

The meaning of Directive 2014/24/EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form

the contract notice is used. The resulting conceptual requirements, such as the process name “open procedure”, are solely due to the use of this notice form and the publication platform. Another meaning, in particular submission to

Procurement regulations, unless they are mandatory for legal reasons, are not associated with this.

Under stipulation of uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered to conclude or join a discount contract in accordance with Section 130a (8) SGB V for the active ingredients mentioned in Section B. Interested pharmaceutical companies can request the participation documents and the contract from the contact address mentioned under I.1. The prerequisite for concluding a contract is that the interested pharmaceutical company must complete and sign the requested participation documents in full. A contract is concluded with each pharmaceutical company that meets the participation requirements. There is no exclusivity. This publication does not involve the award of a public contract in

The meaning of Directive 2014/24/EU or public procurement law. In order to ensure the greatest possible degree of transparency for the intended conclusion of contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form

the contract notice is used. The resulting conceptual requirements, such as the process name “open procedure”, are solely due to the use of this notice form and the publication platform. Another meaning, in particular submission to

Procurement regulations, unless they are mandatory for legal reasons, are not associated with this.